Servier Pharmaceuticals shared a post on LinkedIn:
“Servier is proud to join the neuro-oncology community at SNO2025, where we’ll present clinical and real-world data highlighting our glioma treatment.
As a pioneer in targeted therapies for brain tumors, Servier, is advancing treatment innovation for patients and families affected by Grade 2 IDH-mutant glioma.
Learn more about our research here.”
More posts about Servier.